About Mediar Therapeutics
Mediar Therapeutics is a private company based in Boston, Massachusetts. It has reported $127,884,681 raised in three offerings on Form D since February 2019. Its chief executive is Rahul Ballal.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 10, 2025 | Dec 23, 2025 | $37,849,815of $75.6M target | 18 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Nov 18, 2022 | Dec 2, 2022amended Oct 22, 2024 | $85,034,866fully sold | 17 | $5.0M | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Jan 29, 2019 | Feb 6, 2019 | $5,000,000of $10.0M target | 7 | $714K | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $127,884,681 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Mediar Therapeutics's Form D filed Dec 23, 2025.
Earlier filings also listed Michael Baran (director, last listed Oct 2024), Meredith Fisher (director, last listed Oct 2024), Anja Konig (director, last listed Oct 2024), Stacey Brenner (chief executive officer, last listed Feb 2019), Peter Parker (director, last listed Feb 2019), David de Graaf (director, last listed Feb 2019) and Brian Hubbard (director, last listed Feb 2019).